Improvement of Mutism in a Catatonic Schizophrenia Case by Add-On Treatment with Amantadine

It has been proposed that the pathophysiology of catatonia involves abnormalities in GABAergic, dopaminergic, and glutamatergic systems [3] [4]. We report that adding amantadine, an N-methyl-d-aspartate (NMDA) receptor antagonist [7]/indirect dopamine (DA) agonist, to combined risperidone (dopamine D₂/5-HT_2A receptor antagonist) and diazepam (a benzodiazepine GABA_A receptor agonist) treatment can improve mutism in catatonic-type schizophrenia.

References

• 1 Babington PW, Spiegel DR. Treatment of catatonia with olanzapine and amantadine.  Psychosomatics. 2007;  48 534-536
• 2 Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies.  Arch Gen Psychiatry. 1990;  47 181-188
• 3 Carlsson M, Carlsson A. Schizophrenia: A subcortical neurotransmitter imbalance syndrome?.  Schizophr Bull. 1990;  16 425-432
• 4 Carroll BT, Goforth HW, Thomas C. et al . Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes.  J Neuropsychiatry Clin Neurosci. 2007;  19 406-412
• 5 Geyer MA, Krebs-Thomson K, Braff DL. et al . Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.  Psychopharmacology (Berl). 2001;  156 117-154
• 6 Goforth H. Amantadine in catatonia due to major depressive disorder in a medically ill patient.  J Neuropsychiatry Clin Neurosci. 2007;  19 480-481
• 7 Kornhuber J, Bormann J, Hubers M. et al . Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.  Eur J Pharmacol. 1991;  206 297-300
• 8 Kornhuber J, Bormann J, Retz W. et al . Memantine displaces [³H] MK-801 at therapeutic concentrations in postmortem human frontal cortex.  Eur J Pharmacol. 1989;  166 589-590
• 9 Munoz C, Yulan N, Achaval V. et al . Memantine in major depression with catatonic features.  J Neuropsychiatry Clin Neurosci. 2008;  20 119-120
• 10 Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine.  J Neurol Neurosurg Psychiatry. 1997;  62 404-406
• 11 Poyurovsky M, Weizman R, Weizman A. et al . Memantine for treatment-resistant OCD.  Am J Psychiatry. 2005;  162 2191-2192
• 12 Swerdlow NR, Eastvold A, Karban B. et al . Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies.  Psychopharmacology (Berl). 2002;  161 189-201
• 13 Swerdlow NR, Stephany N, Shoemaker JM. et al . Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons.  Psychopharmacology (Berl). 2002;  164 82-92
• 14 Wynn JK, Green MF, Sprock J. et al . Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial.  Schizophr Res. 2007;  95 134-142

Correspondence